Current Cardiology Reports

, Volume 5, Issue 4, pp 259–265

Optimal medical management of angina

  • Brian Noronha
  • Edward Duncan
  • Jonathan A. Byrne


Coronary artery disease remains one of the principal causes of disability worldwide. Its most common manifestation is angina pectoris. Angina occurs due to an imbalance between myocardial oxygen demand and supply; it is classically precipitated by physical activity, emotion, eating, or cold weather. It is defined as stable when its frequency, severity, duration, time of appearance, and precipitating factors remain unchanged for 60 days. Treatment of patients with stable angina targets a number of factors that underlie its pathophysiology: aspirin as an antiplatelet agent, β-blockade to reduce myocardial oxygen demand, and additional antianginal drugs when symptoms are incompletely controlled by βblockers alone. Furthermore, aggressive treatment of risk factors for the development of coronary artery disease confers a significant mortality benefit. Unstable angina is defined as symptoms developing at rest, on minimal exertion, and of increasing severity, duration, or frequency. It is associated with significant mortality; consequently, early assessment and intervention is essential to prevent worsening ischemia. Treatment includes close in-patient monitoring, administration of antiplatelet and antithrombotic drugs, and a combination of β-blockers, calcium antagonists, and intravenous nitrates where appropriate. Coronary revascularization should be considered in high-risk patients, and when conservative management strategies fail.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Recommended Reading

  1. 1.
    Moher M, Yudkin P, Wright L, et al.: Cluster randomised controlled trial to compare three methods of promoting secondary prevention of coronary heart disease in primary care. Br Med J 2001, 322:1338.CrossRefGoogle Scholar
  2. 2.
    North of England Stable Angina Guideline Development Group: North of England evidence based guidelines development project: summary version of evidence based guidelines for the primary care management angina. Br Med J 1996, 312:827–832.Google Scholar
  3. 3.
    Graves EJ, Kozak LJ: Detailed diagnoses and procedures, National Hospital Discharge Survey, 1996. Vital Health Stat 13 1998:1–151.Google Scholar
  4. 4.
    Armstrong PW, Fu Y, Chang WC, et al.: Acute coronary syndromes in the GUSTO-2b trial: prognostic insights and impact of recurrent ischemia. Circulation 1998, 98:1860–1868.PubMedGoogle Scholar
  5. 5.
    Braunwald E, Antman EM, Beasley JW, et al.: ACC guidelines for management of patients with unstable angina and non-ST segment elevation myocardial infarction. J Am Coll Cardiol 2000, 36:970–1062.PubMedCrossRefGoogle Scholar
  6. 6.
    Hamm CW, Bertrand M, Braunwald E: Acute coronary syndrome without ST segment elevation: implementation of new guidelines: Lancet 2001, 358:1533–1538.PubMedCrossRefGoogle Scholar
  7. 7.
    Ross R: The pathogenesis of atherosclerosis. In Heart Disease. A Textbook of Cardiovascular Medicine. Edited by Braunwald E. Philadelphia: WB Saunders; 1997:1105–1125.Google Scholar
  8. 8.
    Bogaty P, Hackett D, Davies G, Maseri A: Vasoreactivity of the culprit lesion in unstable angina. Circulation 1989, 80:198–205.Google Scholar
  9. 9.
    Davies M, Thomas M, Knapman P, Hangartner R: Intram yocardial platelet aggregation in patients with unstable angina suffering sudden ischaemic death. Circulation 1986, 73:418–427.PubMedGoogle Scholar
  10. 10.
    de Bono D: Investigation and management of stable angina; revised guidelines 1998. Heart 1999, 81:546–555.PubMedGoogle Scholar
  11. 11.
    Gibbons RJ, Chatterjee K, Daley J, et al.: ACC/AHA/ACM-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. (A report of the American College of Cardiology/American Heart Association Task Force on Practise Guidelines.) Circulation 1999, 99:2829–2848.PubMedGoogle Scholar
  12. 12.
    Von Arnim T: Medical therapy to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS): a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators. J Am Coll Cardiol 1995, 25:231–238.CrossRefGoogle Scholar
  13. 13.
    Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival. Lancet 1986, 2:57–66.Google Scholar
  14. 14.
    MERIT-HF Study Group: Effects of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001–2007.CrossRefGoogle Scholar
  15. 15.
    Wassertheil-Smoller S, Oberman A, Blauxfox MD, et al.: The trial of anti-hypertensive Intervention and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk and quality of life. Am J Hypertens 1992, 5:47–48.Google Scholar
  16. 16.
    Silber S: Nitrates: why and how should they be used? Current status of usefulness of nitroglycerin, isosorbide dinitrate, and isosorbide-mononitrate. Eur J Clin Pharm 1990, 3:535–551.Google Scholar
  17. 17.
    Opie LH, Messerli FH: Nifedipine and mortality. Grave defects in the dossier. Circulation 1995, 92:1326–1331.Google Scholar
  18. 18.
    Rehnqvist N, Hjemdahl P, Billing E, et al.: Treatment of stable angina pectoris with calcium antagonists and beta-blockers. The APSIS study. Cardiologia 1995, 40(Suppl 1):301.PubMedGoogle Scholar
  19. 19.
    Savonitto S, Ardissiono D, Egstrup K, et al.: Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 1996, 27:311–316.PubMedCrossRefGoogle Scholar
  20. 20.
    Rice KR, Gervino E, Jarisch WR, Stone PH: Effects of nifedipine on myocardial perfusion during exercise in chronic stable angina. Am J Cardiol 1990, 65:1097–1101.PubMedCrossRefGoogle Scholar
  21. 21.
    Dargie HJ, Ford I, Fox KM, Hillis WS: Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomised trial. Lancet 2002, 359:1269–1275. This study demonstrated a significant mortality benefit with nicorandil therapy, due to a reduction in major coronary events in patients with stable angina.CrossRefGoogle Scholar
  22. 22.
    Juul-Moller S, Edvardsson N, Jahnmatz B, et al.: Double blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992, 340:1421–1425.PubMedCrossRefGoogle Scholar
  23. 23.
    A randomised, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet 1996, 348:1329–1339.Google Scholar
  24. 24.
    Danhlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study: a randomised trial against atenolol. Lancet 2002, 359:995–1003.CrossRefGoogle Scholar
  25. 25.
    Heart Outcomes Prevention Evaluation Study investigators: Effects of ramipril on cardiovascular and microvascular outcomes in patients with diabetes mellitus: Results of the HOPE and MICRO-HOPE sub-study. Lancet 2000, 355:253–259.CrossRefGoogle Scholar
  26. 26.
    Gould AL, Rossouw JE, Santanello NC, et al.: Cholesterol reduction yields clinical benefits: impact of statin trials. Circulation 1998, 97:946–952.PubMedGoogle Scholar
  27. 27.
    Pignone M, Phillips C, Mulrow C: Use of lipid lowering drugs for primary prevention of coronary heart disease: a metaanalysis of randomised trials. Br Med J 2000, 321:983–986.CrossRefGoogle Scholar
  28. 28.
    Hjermann I, Velve Byre K, Holme I, Leren P: Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from Oslo study Group of a randomised trial in healthy men. Lancet 1981, 2:1303–1310.PubMedCrossRefGoogle Scholar
  29. 29.
    Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type-2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229–234.PubMedCrossRefGoogle Scholar
  30. 30.
    Stamler J, Vaccarao O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434–444.PubMedCrossRefGoogle Scholar
  31. 31.
    Intensive blood glucose control with sulphonylureas or insulin compared to conventional treatment and risk of complications in patients with type-2 diabetes (UKPDS-33). Lancet 1998, 352:837–853.Google Scholar
  32. 32.
    Gaede N, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 384:383–393.CrossRefGoogle Scholar
  33. 33.
    Braunwald E: Unstable angina: a classification: Circulation 1989, 80:410–414.PubMedGoogle Scholar
  34. 34.
    Calvin JE, Klein LW, VandenBerg BJ, et al.: Risk strafication in unstable angina. Prospective validation of the Braunwald classification. JAMA, 1995, 273:136–141.PubMedCrossRefGoogle Scholar
  35. 35.
    Wilcox I, Freedman SB, McCredie RJ, et al.: Risk of adverse outcome in patients admitted to the coronary care unit with suspected unstable angina pectoris. Am J Cardiol 1998, 64:845–848.CrossRefGoogle Scholar
  36. 36.
    Dangas G, Mehran R, Wallestein S, et al.: Correlation of angiographic morphology and clinical presentation in unstable angina. J Am Coll Cardiol 1997, 29:519–525.PubMedCrossRefGoogle Scholar
  37. 37.
    Theraux P, Ouimet H, McCans J, et al.: Aspirin, heparin or both to treat unstable angina. N Engl J Med 1988, 319:1105–1111.CrossRefGoogle Scholar
  38. 38.
    The CURE investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndrome without STsegment elevation. N Engl J Med 2002, 345:494–502. This major trial demonstrated the benefit of additional antiplatelet therapy with clopidogrel in acute coronary syndromes. Treatment with clopidogrel reduced the risk of MI and recurrent ischemia, with a trend toward lower rates of stroke and death from cardiovascular causes.Google Scholar
  39. 39.
    The PURSUIT trial investigators: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT). N Engl J Med 1998, 339:436–443.CrossRefGoogle Scholar
  40. 40.
    The PRISM Study investigators: A comparison of aspirin plus tirofiban with aspirin in unstable angina. N Engl J Med 1998, 338:1498–1505.CrossRefGoogle Scholar
  41. 41.
    Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med. 1998, 338:1488–1497.Google Scholar
  42. 42.
    The CAPTURE investigators: Randomised placebo controlled trial of abxicimab before and during coronary intervention in refractory angina. The CAPTURE study. Lancet 1997, 336:1429–1435.Google Scholar
  43. 43.
    The PARAGON investigators: Randomised placebo controlled trial of lamifiban, heparin or both in unstable angina. Circulation 1998, 97:2386–2395.Google Scholar
  44. 44.
    Boersma E, Harrington RA, Moliterno DJ, et al.: Platelet glycoprotein 11b/111a inhibitors in acute coronary syndrome-A meta-analysis of all major randomised clinical trials. Lancet 2002, 359:189–198.PubMedCrossRefGoogle Scholar
  45. 45.
    Oler A, Whooley MA, Oler J, Grady D: Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with uunstable angina. A meta-analysis. JAMA 1996, 276:811–815.PubMedCrossRefGoogle Scholar
  46. 46.
    FRISC study group: Low-molecular weight heparin during instability in coronary artery disease. Lancet 1996, 347:561–568.Google Scholar
  47. 47.
    The FRAXIS study group: Comparison of two treatment duration (6 days and 14 days) of a low-molecular weight heparin with a 6 day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAXIS (Fraxiparine in Ischemic Syndrome). Eur Heart J 1999, 20:1553–1562.CrossRefGoogle Scholar
  48. 48.
    Antman EM, McCabe CH, Premmereur J, et al.: Enoxaparin prevents death and cardiac ischemic events in unstable angina / non-Q wave myocardial infarction: results of Thrombolysis in Myocardial Infarction (TIMI) 2b trial. Circulation 1999, 100:1593–1601.PubMedGoogle Scholar
  49. 49.
    Cohen M, Demers C, Gurfinkel EP, et al.: A comparison of low molecular weight heparin with unfractionated heparin in unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997, 96:61–68.Google Scholar
  50. 50.
    Cohen M, Denmers C, Gurfinkel EP, et al.: Efficacy and Safety of subcutaneous Enoxaparin in Non-Q wave Coronary Events Study Group (ESSENCE). A comparison of low-molecular weight heparin with unfractionated heparin for coronary artery disease. N Engl J Med 1997, 337:447–452.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2003

Authors and Affiliations

  • Brian Noronha
    • 1
  • Edward Duncan
    • 1
  • Jonathan A. Byrne
    • 1
  1. 1.Department of CardiologyGKT School of MedicineLondonUK

Personalised recommendations